Skip to main content

Table 2 Adverse events

From: Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis

  Chemoradiation
(N = 227)
Chemotherapy
(N = 82)
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Alopecia 7 (3,1) 2 (0,9)
Nausea/vomiting 92 (40.5) 47 (20.2) 20 (8.8) 1 (0.4) 34 (41.5) 25 (30.5) 4 (4.9)
Diarrhea 91 (40.1) 40 (17.6) 20 (8.8) 3 (1.3) 35 (42.7) 16 (19.5) 6 (7.3) 2 (2.4)
Anorexia 46 (20.3) 38 (16.7) 18 (7.9) 10 (12.2) 7 (8.5) 1 (1.2)
Asthenia 47 (20.7) 23 (10.1) 21 (9.3) 16 (19.5) 22 (26.8) 2 (2.4)
Dysphagia 7 (3.1) 2 (0.9) 3 (1.3) 2 (2.4) 2 (2.4)
Neuropathy 38 (46.3) 18 (22) 2 (2.4)
Mucositis 37 (16.3) 22 (9.7) 9 (4.0) 1 (0.4) 17 (20.7) 2 (2.4) 1 (1.2)
Neutropenia 16 (7.0) 34 (15.0) 48 (21.1) 38 (16.7) 4 (4.9) 20 (24.4) 14 (17.1) 3 (3.7)
Febrile neutropenia 6 (2.6) 2 (0.9) 1 (0.4)
Anemia 58 (25.6) 29 (12.8) 8 (3.5) 1 (0.4) 1 (0.4) 48 (58.5) 16 (19.5) 5 (6.1)
Thrombocytopenia 54 (23.8) 14 (6.2) 5 (2.2) 1 (0.4) 29 (35.4) 6 (7.3) 4 (4.9)
Renal toxicity 6 (2.6) 3 (1.3) 2 (0.9) 3 (3.7) 3 (3.7) 1 (1.2)
Hand-foot syndrome 7 (3.1) 1 (0.4) 30 (36.6) 5 (6.1) 2 (2.4)